Trial · NCT05422274
Effect of Transcranial Pulse Stimulation on ADHD
NCT05422274, Not applicable, Completed, The Hong Kong Polytechnic University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effect of Transcranial Pulse Stimulation on ADHD. Trials, record NCT05422274. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05422274
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Transcranial Pulse Stimulation on ADHD
- NCT number
- NCT05422274
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 32 participants, actual
- Lead sponsor
- The Hong Kong Polytechnic University
- Conditions
- ADHD
- Interventions
- Transcranial Pulse Stimulation
- First posted
- 2022-06-16
- Last updated
- 2025-03-13
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Attention deficit, hyperactivity impulse and oppositional defiance | Changes in SNAP-IV scores from baseline at 3 months | The Swanson, Nolan, and Pelham Rating Scale (SNAP IV) will be used to measure participants' attention deficit, hyperactivity impulse and oppositional defiance. SNAP IV consists of 26 items summarized into three factors: attention deficit, hyperactivity impulse, and oppositional defiance. Parents based on their general impressions on their children and rate the severity of symptoms on a Likert scale (0-3). Mean score \<1 indicate "normal" or "remission"; Mean score of 1 is defined as the demarcation for attention deficit and hyperactivity impulsivity; mean score \>2 indicated "abnormal". SNAP-IV is a reliable and valid scale used in RCTs and has good psychometric properties in the Chinese population. |
| Secondary | Clinical global impression | Changes in CGI from baseline at 3 months | CGI-S is a 7-point clinician rating scale is based upon observed and reported symptoms, behaviour, and function in the past seven days. CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. |
| Secondary | Executive function | Changes in Stroop test from baseline at 3 months | Stroop test is a neuropsychological test commonly used to assess the inhibition control component of executive function and test the subject's ability to inhibit cognitive interference that occurs when the processing the target stimulus feature is impeded by the simultaneous processing of a second stimulus attribute. |
| Secondary | The ADHD Rating Scale-IV | Changes in ADHD RS-IV from baseline at 3 months | ADHD RS-IV is a widely used ADHD scale comprising 18 items. Participant's parent rates the frequency of each symptom on the scale. Each item scores on a 4-point Likert scale of 0-3 (0: never or rarely; 1: sometimes; 2: often; 3: very often). The 9 odd items evaluate attention deficits, composing the Inattention subscale (or IA); the 9 even items evaluate Hyperactivity Impulsivity, composing the Hyperactivity Impulsivity (or HI) subscale; the total score is the sum of all the scores on the 18 items. The ADHD RS-IV is a reliable and valid scale in the Chinese population. |
| Secondary | Neuroimaging | MRI will be assessed at baseline at immediately and 2 weeks after post-stimulation | Participants will receive pre and post treatment MRI scan to measure any changes in structural and functional connectivity changes in the brain. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Secondary outcome |
Source ConductCognition
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05422274
GET https://conductscience.org/api/trials/v1/NCT05422274/registered